Hsp90α、CER及AFP预测原发性肝癌患者TACE疗效的价值  

Predictive value of Hsp90α,CER and AFP for the curative effect of TACE in patients with primary liver cancer

作　　者：姚冬梅 田添[2] YAO Dongmei;TIAN Tian(Department of Oncology,Linquan County People's Hospital,Fuyang,Anhui,China,236400;Depart-ment of Oncology,Fuyang People's Hospital,Fuyang,Anhui,China,236000)

机构地区：[1]临泉县人民医院肿瘤内科,安徽阜阳236400 [2]阜阳市人民医院肿瘤内科,安徽阜阳236000

出　　处：《分子诊断与治疗杂志》2024年第8期1399-1402,共4页Journal of Molecular Diagnostics and Therapy

基　　金：安徽省卫生健康委科研项目(AHWJ2021a075)。

摘　　要：目的 分析血清热休克蛋白90(Hsp90α)、铜蓝蛋白(CER)及甲胎蛋白(AFP)预测原发性肝癌患者肝动脉化疗栓塞术(TACE)疗效的价值。方法 选取2020年1月至2023年1月临泉县人民医院收治的70例行TACE治疗的原发性肝癌患者作为研究对象,于术后2个月采用mRECIST标准评价术后疗效,根据疗效差异将其分为良好组和不良组。比较两组的基线资料、血清Hsp90α、CER及AFP水平差异,绘制ROC曲线分析TACE治疗前上述血清指标对TACE后疗效的预测价值。结果 入组对象经TACE治疗有效率为72.86%。良好组和不良组临床分期、肿瘤边界比较,差异均有统计学意义(t/χ^(2)=5.440、10.928,P<0.05)。TACE治疗前不良组血清Hsp90α、CER及AFP水平均高于良好组,差异有统计学意义(t=2.501、2.082、2.964,P<0.05),TACE治疗结束后不良组血清Hsp90α、CER及AFP水平均高于良好组,差异有统计学意义(t=7.196、6.866、8.687,P<0.05)。TACE治疗前,随着临床分期增加,血清Hsp90α、CER、AFP值均不断升高(F=4.966、4.817、7.878,P<0.05);肿瘤边界不规则血清Hsp90α、CER及AFP水平高于肿瘤边界规则的患者,差异有统计学意义(t=8.169、3.434、10.276,P<0.05)。ROC曲线分析显示,TACE治疗前,血清Hsp90α、CER及AFP水平联合预测TACE后疗效的AUC最大(P<0.05)。结论 血清Hsp90α、CER及AFP水平检测可以较好预测TACE后临床疗效,上述指标可以为临床干预提供一定依据。Objective To analyze the predictive value of serum Hsp90α,CER and AFP for the cura⁃tive effect of TACE in patients with primary liver cancer.Methods A total of 70 patients with primary liver can⁃cer undergoing TACE at Linquan County People's Hospital were enrolled as research subjects between January 2020 and January 2023.The postoperative curative effect was evaluated using mRECIST at 2 months after sur⁃gery,and the treatment response rate was calculated.Based on the curative effect,patients were divided into a good group and a poor group.The baseline data,levels of serum Hsp90α,CER,and AFP were compared between the two groups.The predictive value of the serum indicators mentioned above for the curative effect of TACE was analyzed using ROC curves.Results In the 70 patients with primary liver cancer,the response rate of TACE was 72.86%.There were significant differences in clinical staging and tumor boundary between the good group and poor group(t/χ^(2)=5.440,10.928,P<0.05).Before TACE,levels of serum Hsp90α,CER,and AFP in the poor group were higher than those in the good group(t=2.501,2.082,2.964,P<0.05).After TACE,levels of serum Hsp90α,CER,and AFP in the poor group were higher than those in the good group(t=7.196,6.866,8.687,P<0.05).Before TACE,levels of serum Hsp90α,CER,and AFP increased with the increase of clinical staging(F=4.966,4.817,7.878,P<0.05).The levels of serum Hsp90α,CER,and AFP in patients with irregular tu⁃mor boundaries were higher than those with regular tumor boundaries(t=8.169,3.434,10.276,P<0.05).ROC curve analysis showed that the AUC of serum Hsp90αcombined with CER and AFP before TACE for predicting the curative effect was the greatest(P<0.05).Conclusion Serum levels of Hsp90α,CER,and AFP can help predict the clinical effectiveness of TACE.These markers can provide a basis for clinical intervention.

关 键 词：原发性肝癌 肝动脉化疗栓塞术 热休克蛋白90 铜蓝蛋白 甲胎蛋白 

分 类 号：R735.7[医药卫生—肿瘤]